If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: 2.50 (5.81%)
Spread: 1.00 (2.222%)
Open: 43.10
High: 45.60
Low: 43.10
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta plans fundraise to fund clinical development

Wed, 28th Feb 2024 20:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Issues trading update to December 31. Expects 2023 revenue of EUR13.4 million, nearly three times 2022's EUR4.8 million. But, predicts adjusted loss before interest, tax, depreciation and amortisation widens to EUR4.1 million from EUR2.0 million. Says this reflects expenses made in the development of artificial intelligence products, costs associated with the listing of classes A and B shares into the Access segment of the AQSE Growth Market, and the acquisition of companies.

----------

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Plans to raise GBP13.8 million via placing and subscription at 50 pence per share. In addition, proposes to raise further GBP6.2 million via a conditional placing and GBP6.8 million by a retail offer. Proceeds to be used to initiate and progress the dose expansion and Phase 2 efficacy studies for its lead pre|CISIONTM clinical programme, AVA6000, as well as for general working capital until the end of 2025.

----------

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Receives conversion notice on February 20 from Macquarie Bank Ltd for GBP80,000 of convertible bonds from the GBP5.0 million convertible bond facility announced on January 25. Further, plans to seek alternative financing options for its inorganic acquisition strategy, rather than drawing upon the facility any further.

----------

Beacon Rise Holdings PLC - acquisition company - Notes resolution at today's emergency general meeting was backed by 100% of shareholders. Explains vote extends time frame for Beacon Rise to pursue a suitable acquisition target for a further 12 months, to March 24, 2025.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - At the general meeting held Wednesday, announces the ordinary resolution relating to the adoption of the new investment policy was duly passed by shareholders. Around 87% of shareholders supported the motion.

----------

Beacon Energy PLC - Isle of Man-registered oil and gas company - Plans to raise GBP2.6 million via placing and retail offer at 0.05 pence per share. Explains the placing will be effected by way of an accelerated bookbuild. Proceeds to be used for further drilling, payment of outstanding costs and general working capital. States cash resources at February 16 totalled EUR1.2 million. Notes due to

delays during the drilling of the SCHB-2(2.) well, the company has an outstanding payables position due to a small number of contractors. Of this, around EUR1.1 million is due prior to the end of April with the balance of around EUR1.4 million due between May and August and expected to be funded from production post side-track. Beacon Energy expects to deliver operating cash flows during 2024 of around EUR40,000, EUR300,000, EUR800,000 and EUR1.3 million per month, at flow rates of 150, 300, 600 and 900 barrels of oil per day.

----------

Asian Energy Impact Trust PLC - investment company focused on sustainable energy infrastructure projects - Notes significant minority vote at Wednesday's general meeting, just over 20%, against resolutions 1, 2 and 3. Pledges to continue to seek to engage with shareholders to discuss any views they may have and will take into account any feedback around their concerns. Vote 1 was to receive the 2022 annual report and accounts of the company. Vote 2 to approve the directors' remuneration report. Vote 3 was to approve the directors' remuneration policy.

----------

Contango Holdings PLC - Holds 70% interest in the Muchesu mine in Zimbabwe - Reports pretax loss in the six months to November 30 of GBP1.4 million, narrowed from GBP1.8 million the year prior. Basic and diluted loss per share totalled 0.27p, compared to 0.55p. Administrative fees and other expenses fall to GBP879,951 from GBP1.3 million.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
6 Apr 2023 10:09

Avacta opens first US clinical investigator sites

(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.

Read more
5 Apr 2023 12:51

Avacta doses first patient in higher-dose oncology cohort

(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.

Read more
5 Apr 2023 12:12

Avacta doses first patient in fifth cohort of AVA6000 phase 1 study

(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.

Read more
27 Mar 2023 13:44

Avacta to present tumour medicine data at cancer research meeting

(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
13 Mar 2023 10:08

Avacta has 'no relationship' with failed tech-focussed bank

(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.

Read more
17 Jan 2023 17:16

Avacta reports positive progress in chemotherapy trial

(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
8 Nov 2022 13:51

Avacta raises GBP64 million to finance Launch Diagnostics purchase

(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.

Read more
18 Oct 2022 12:40

Avacta plans to raise GBP62 million; buys Launch Diagnostics

(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.

Read more
18 Oct 2022 11:12

Avacta buying Launch Diagnostics for initial £24m

(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.

Read more
29 Sep 2022 11:56

Avacta losses narrow as it progresses clinical programmes

(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.

Read more
29 Sep 2022 11:30

Avacta narrows loss, multiplies revenue thanks to Therapeutics divison

(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.

Read more
5 Sep 2022 11:07

AIM WINNERS & LOSERS: Avacta gets approval; Jubilee's Roan at capacity

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
5 Sep 2022 10:10

Avacta shares up as drug approved for soft tissue sarcoma treatment

(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.